INTERMUNE
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, they are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.
INTERMUNE
Social Links:
Industry:
Biotechnology Developer Platform Health Care Therapeutics
Founded:
1998-01-01
Address:
Brisbane, California, United States
Country:
United States
Website Url:
http://www.intermune.com
Total Employee:
251+
Status:
Active
Contact:
(415) 466-2200
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
SPF ASP.NET IIS DigiCert SSL ASP.NET 4.0 ASP.NET Ajax IIS 7 GeoTrust SSL Rackspace ASP.NET 2.0
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - InterMune
Sofinnova Investments
Sofinnova Investments investment in Venture Round - InterMune
Official Site Inspections
http://www.intermune.com
- Host name: 199.59.243.227
- IP address: 199.59.243.227
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
